Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$468.63 USD

468.63
819,091

-9.21 (-1.93%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $468.63 0.00 (0.00%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track

by Zacks Equity Research

LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.

    Stryker Recalls Sage Unit Products, Guidance Takes a Hit

    by Zacks Equity Research

    Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.

      Patterson Companies (PDCO) Beats on Q1 Earnings, Keeps View

      by Zacks Equity Research

      Patterson Companies' (PDCO) Animal Health business continues to contribute to the bottom line. Stable fiscal 2018 guidance instills investor confidence.

        Why IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet

        by Zacks Equity Research

        IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.

          Civitas Solutions (CIVI) to Acquire Habilitative Services

          by Zacks Equity Research

          Civitas Solutions' (CIVI) proposed acquisition of Habilitative Services will aid the company in capturing the lucrative Minnesota market.

            Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat

            by Zacks Equity Research

            Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.

              Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm

              by Zacks Equity Research

              Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.

                PerkinElmer Strong on Product Lineup Amid Integration Risks

                by Zacks Equity Research

                PerkinElmer's (PKI) expanding product portfolio helps it gain global market share. However, the company's regular acquisitions pose integration risks.

                  Medtronic (MDT) Beats Q1 Earnings, Misses Revenue Estimates

                  by Zacks Equity Research

                  Medtronic (MDT) rides high in Q1 on strength in three major business segments.

                    PAREXEL Ties Up With Osaka International Cancer Institute

                    by Zacks Equity Research

                    We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.

                      Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

                      by Zacks Equity Research

                      Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.

                        Quality Systems Professional Service a Drag, Competition Rife

                        by Zacks Equity Research

                        Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.

                          Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio

                          by Zacks Equity Research

                          Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.

                            BioScrip's Infusion Business Strong, Dull 2017 View a Drag

                            by Zacks Equity Research

                            BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                              Zimmer (ZBH) Plagued by Various Internal and External Issues

                              by Zacks Equity Research

                              Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.

                                Myriad Genetics' EndoPredict Gets Positive Coverage Decision

                                by Zacks Equity Research

                                Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.

                                  Accuray's Radixact Now Used by Boise Summit Cancer Center

                                  by Zacks Equity Research

                                  Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.

                                    Globus Medical's Robotic Guidance System Gets FDA Approval

                                    by Zacks Equity Research

                                    Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.

                                      Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance

                                      by Zacks Equity Research

                                      The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.

                                        Here's Why Investors Should Buy Edwards Lifesciences Now

                                        by Zacks Equity Research

                                        Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

                                          Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                                          by Zacks Equity Research

                                          IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

                                            McKesson Banks on Distribution Business Amid Pricing Woes

                                            by Zacks Equity Research

                                            McKesson (MCK) entered fiscal 2018 with an assumption of branded inflation in the mid-single digits. Pricing pressure in the independent retail pharmacy channel is a headwind.

                                              BioTelemetry Hits a 52-Week High: What's Driving the Stock?

                                              by Zacks Equity Research

                                              BioTelemetry (BEAT) is putting efforts in product innovation through research and development. The company recently announced the acquisition of LifeWatch AG in a deal valued at about $280 million.

                                                Invacare (IVC) Introduces TDX SP2 Power Wheelchair Globally

                                                by Zacks Equity Research

                                                Invacare Corporation's (IVC) newly launched TDX SP2 Power Wheelchair would greatly help in capturing the highly competitive global wheelchair market.

                                                  PRA Health Sciences (PRAH) Prices Secondary Stock Offering

                                                  by Zacks Equity Research

                                                  PRA Health Sciences' (PRAH) move to procure funds through secondary offering is likely to enhance its bottom line and shareholders' returns.